Guan, X., Wang, L., Cao, Y., Shi, F., Xu, H., Ding, J., Wu, M. and Li, H. 2023. A Erratum on Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China. Health Decision. 1, (Nov. 2023). DOI:https://doi.org/10.54844/hd.2023.0498.